Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our performance in the fourth quarter ultimately enabled us to generate growth in sales of these products in excess of 250% for the full year fiscal 2023, fueling the 22% growth in the Medical Device segment product sales that we achieved this year |
| We were pleased to announce the commercial launch of Preside in October and believe it will raise the standard of performance for hydrophilic coatings and facilitate the use and functionality of catheters across many complex applications and secure our leadership and competitive position |
| And we drove strong revenue and cash flow from our Medical Device coatings, offerings and IVD businesses on a combined basis |
| And lastly, we significantly enhanced our cash balance by achieving a $27 million milestone payment related to the SurVeil PMA approval and raising $19.3 million in net proceeds under our new five-year credit agreement |
| Excluding this license fee revenue, our Medical Device segment delivered 15% revenue growth year-over-year, fueled by increased royalties and license fee revenue from our Performance Coatings, product sales, including major contributions from our Pounce Arterial Thrombectomy platform and R&D services revenue |
| We're also quite pleased to see robust contributions from our In Vitro Diagnostics or IVD segment as well |
| As we had anticipated in our last earnings call, our IVD segment returned to growth in the fourth quarter, increasing 7% year-over-year to $6.9 million, with customers returning to more normalized purchasing patterns after taking steps in recent quarters to manage COVID era elevated inventory levels |
| In addition to our revenue performance in the fourth quarter, we achieved notable year-over-year improvements in our operating results, delivering adjusted EBITDA of $1.7 million, a $4.2 million improvement compared to the fourth quarter of last year |
| I think going distal in the neural crossing really challenging lesions like total chronic occlusions it really gives us an advantage with this coating relative to even some of our internal coatings, but more importantly to competitive coatings |
| So we're excited |
| Our financial performance in the fourth quarter culminated in a strong year overall |
| So all the momentum we believe is stacked positively |
| Lastly, from a partnership standpoint, we believe Abbott is well positioned to take advantage of these attractive market dynamics in 2024 and the years to come with a significant sales and marketing presence in the vascular space and a complementary suite of existing products including sense and atherectomy devices |
| This development and regulatory clearance of Preside, our new coating technology reflects our continued commitment to innovation and industry leadership in the medical device coatings industry, which has been a defining area of differentiation and a core competency for Surmodics throughout much of our history |
| We are pleased to bring fiscal 2023 to a strong close by delivering on the three strategic objectives that we laid out at the beginning of the year, which as a reminder were as follows: first to achieve FDA pre-market approval or PMA for our SurVeil DCB and support our partner Abbott as they prepare to commercialize the product; second, advance the initial commercialization of our Pounce Arterial Thrombectomy and Sublime Radial platforms; and third, drive revenue and cash flow growth of our Medical Device Performance Coatings offerings and IVD businesses |
| And so that tell you the appetite and signal and our strength of our competitive position |
| With respect to each of these key areas, we believe we are well positioned to support Abbott's future launch and initial commercialization of the SurVeil DCB |
| These benefits will enable physicians to -- ultimately to reach distal treatment sites and deliver improved therapeutic outcomes |
| The fourth quarter benefited from improved US procedure volumes |
| We have an incredible sales organization |
| We're energized by our recent pace of progress and the prospect of bringing SurVeil DCB to physicians and patients, and we're equally excited of its potential as a key growth catalyst for the following reasons |
| So feel good at where we are |
| We believe that this maybe favorable to increasing paclitaxel drug-coated balloon market adoption |
| Our diagnostics business benefited from strength in our microarray slide and antigen offerings |
| And Brooks, so last thing just to pile on, is if there is any sentiment that Tim and I are not in our legacy business our core coatings offerings and diagnostics Preside is -- the Preside coating is a remarkable achievement |
| We're also pleased to see the resolution in the marketplace about potential risks posed by paclitaxel-coated devices |
| Its patented coating technology provides unmatched uniformity and consistency of drug distribution along with lower particulate generation and downstream emboli |
| Our revenue performance exceeded the high end of our guidance range, which implied year-over-year growth of 5% for the fourth quarter due to strong performance in both of our business segments |
| With durable and profitable core businesses, a portfolio and pipeline of key catalysts and more than $45 million of cash and investments to support our operations and access to approximately $61 million in available debt capital to provide additional financial flexibility, we believe we are strategically positioned for future success |
| I don't know a single other product and again it's early innings that has better patient outcomes right much better health care economics and a huge impact on patient satisfaction |
| Statement |
|---|
| Importantly, our total revenue performance in the fourth quarter was impacted by a $1 million headwind related to the year-over-year decline in the SurVeil DCB license fee revenue |
| Revenue from our IVD business decreased 3% in fiscal 2023 as customers focused on reducing safety stock levels due to lower demand across the industry for COVID testing products and the normalization of the supply chain |
| Refining -- first year, we'll refine that model but you can imagine the first year predictability without those assumptions and history of those assumptions being validated it's going to be challenging for us |
| As we discussed on last quarter's call, the decrease was expected and was driven by the adverse mix impact from increased device product sales, which have lowered product gross margins from under-absorption and production inefficiencies including expiration of inventory associated with low production volumes during the scale-up phase following our initial commercialization |
| We expect fiscal 2024 total revenue to range from $116 million to $121 million, representing a decrease of 13% to 9% |
| Our Medical Device business reported an operating loss of $2.4 million compared to $6.2 million in the prior year period, reflecting our disciplined expense management, favorability and timing of operating expenditures, and broad-based revenue growth |
| And so we have to be cautious on how we make those estimates going forward |
| This growth was offset in part by a decrease in proprietary specialty catheter product sales due to the completion of a customer development program |
| We had to unfortunately reduce the size of the sales team by a lot right? And so -- and what we had to do at that point because we have to make sure we got to hit our revenue plan the incentives for the sales team when you look at a $4,00-plus product in Pounce versus several hundred dollar product in Sublime catheters we were compelled to redirect the team that we've had towards making sure we're able to hit that revenue |
| SG&A expense decreased $1 million or 7% due to lower direct sales headcount compared to the prior year period related to the aforementioned spending reduction plan |
| SurVeil Drug Coated Balloon license fee revenue declined $1 million or 48% to $1.1 million corresponding with the decrease in TRANSCEND clinical trial costs |
| GAAP net income was $6.7 million or $0.47 per diluted share compared to a net loss of $14.7 million or a loss of $1.06 per diluted share in the prior year period |
| I have no doubt |
| Please be advised that actual results could differ materially from those stated or implied by Surmodics' forward-looking statements, resulting from certain risks and uncertainties including those described in the company's SEC filings |
| This again, despite the $1 million headwind from the year-over-year decline in SurVeil license fee revenue |
| Non-GAAP adjusted EBITDA was $1.7 million compared to adjusted EBITDA loss of $2.5 million in the prior year period |
| Is that right? I know you're not going to break out the sales or anything, but can you just qualitatively comment on how the two are doing relative to each other? Gary Maharaj It has been Mike and one of the reasons for that remember in the whole debacle with the PMA not-approvable letter the VI commercial team took the largest hit in the company |
| You expect it to tick down to closer to $44 million next year |
| New intellectual property and for many customers in that business, especially in the neurovascular segment it's unmatchable |
| We expect R&D expense to range from $43 million to $44 million representing, a decrease of 8% to 6% |
Please consider a small donation if you think this website provides you with relevant information